Setterwalls has advised Guard Therapeutics in connection with private placement of approximately SEK 120 million

Setterwalls has advised Guard Therapeutics International AB (publ) in connection with private placement of approximately SEK 120 million.

Guard Therapeutics International AB (publ) is a Swedish biotech company that identifies and develops new therapies for diseases with a great medical need for more effective treatments. The company’s investigational drug RMC-035 is being developed as a kidney protective treatment in connection with open heart surgery and kidney transplantation.

Among the subscribers, there are a number of institutional, professional and specialist investors, including Stiftelsen Industrifonden, Swedbank Robur Fonder, Strand Kapitalförvaltning and Arctic Asset Management. In total, the company receives approximately SEK 120 million before transaction costs. The net proceeds are intended to be used to secure the completion of the Company’s phase 2 study (AKITA) and to finance selected preparatory phase 3 activities including CMC development.